United States: Capitol Hill Healthcare Update - May 13, 2019

Below is this week's "Capitol Hill Healthcare Update," which is posted on Mondays when Congress is in session.

HOUSE TO VOTE ON BILL COMBINING ACA, DRUG PRICING PROVISIONS

The House is scheduled to vote on legislation Thursday that would package new funding for state-based marketplaces and enrollment outreach efforts under the Affordable Care Act (ACA), with provisions designed to lower prescription drug prices.

Some of the drug pricing provisions enjoyed bipartisan support when considered earlier this year in the Energy and Commerce Committee and the Judiciary Committee. But House Republicans aren't expected to support the overall bill because of the ACA funding and provisions that would roll back the Trump administration's plan to lower insurance premiums for healthier Americans, which Democrats have derided as "junk" insurance plans.

The drug pricing provisions include legislation by Rep. David Cicilline, D-R.I., to allow generic drug companies to gain quicker access to treatments approved under the Food and Drug Administration's risk evaluation and mitigation systems safety protocol. It also would allow civil suits against drugmakers that refuse to provide samples for bioequivalence testing of a generic version of a brand-name drug.

Also included is legislation by Rep. Bobby Rush, D-Ill., that would prohibit patent settlements with brand-name manufacturers that delay a generic drug's entry into the market. A provision by Rep. Kurt Schrader, D-Ore., would prevent a generic drug company from delaying market entry of another generic drug.

The underlying bill, by Rep. Lisa Blunt Rochester, D-Del., would provide $200 million for states to create insurance exchanges for individuals and small businesses to purchase coverage, provide $100 million for ACA navigators to aid consumers enrolling in health plans, and block a Trump administration plan to sell short-term health plans.

DEMOCRATS' BILL WOULD BOOST SPENDING ON OPIOID CRISIS

Sen. Elizabeth Warren, D-Mass., and House Oversight Chairman Elijah Cummings, D-Md., introduced sweeping legislation last week that would spend $100 billion over the next decade to address the opioid crisis.

The bill would bolster funding for evidence-based treatment and establish new state grants to help workers who are at risk of or struggling with addiction to maintain or find employment while in treatment and recovery.

Cummings said Congress could pay for the new funding "by rolling back just a fraction of the massive tax cuts recently granted to opioid manufacturers and other drug companies [that] played such a key role in creating this crisis."

BIPARTISAN SUPPORT FOR TRUMP'S POSITION ON SURPRISE BILLING

President Donald Trump's urging last week for Congress to address unexpected bills for out-of-network medical care drew bipartisan support from key congressional leaders.

House Ways and Means Committee Chairman Richard Neal, D-Mass., and the top Republican on the panel, Rep. Kevin Brady, R-Texas, said in a joint statement that they were willing to work across party lines and with the White House to find a bipartisan solution to protect patients from surprise medical billing.

House Energy and Commerce Committee Chairman Frank Pallone, D-N.J., and the committee's ranking Republican, Rep. Greg Walden, R-Ore., said they hope to announce a bipartisan solution "soon."

The need to address surprise medical billing is a rare area of bipartisan agreement, but an actual solution may be challenging to achieve as physicians, hospitals and insurers lobby to not bear a disproportionate burden of solving the issue.

Sens. Bill Cassidy, R-La., Michael Bennet, D-Colo., and Maggie Hassan, D-N.H., are working on bipartisan legislation. Senate HELP Committee Chairman Lamar Alexander, R-Tenn., said he and the panel's top Democrat, Sen. Patty Murray, D-Wash., would introduce legislation this summer putting limits on surprise billing.

ALEXANDER: TRUMP DTC DRUG RULE 'SMART IDEA'

A key senator last week praised a Trump administration final regulation that would require pharmaceutical manufacturers to state the list price of a 30-day supply of any drug covered by Medicare or Medicaid in their direct-to-consumer advertising.

"The Trump administration rule is a smart idea because the more consumers know about drug prices, the more likely those prices are to be lower," said Senate HELP Committee Chairman Lamar Alexander, R-Tenn.

Several pharmaceutical manufacturers are voluntarily including pricing information in their consumer advertising. But the industry opposes requiring list prices in ads because few if any consumers pay list prices and consumers' out-of-pocket costs are determined by their insurance policies.

HOUSE PANEL APPROVES HHS' BUDGET

The House Appropriations Committee last week approved on a party-line vote the fiscal 2020 spending bill for the Department of Health and Human Services (HHS).

The 30-23 vote sends the bill to the House floor, where a vote hasn't been scheduled. The Senate is separately working on its HHS appropriations bill, with potential committee consideration in early June.

The Democratic House and Republican Senate are likely headed for a political confrontation over the spending package, which includes thorny policy and funding issues on abortion, immigration and the Affordable Care Act.

The House bill would provide HHS with $99 billion, excluding appropriated money for the Food and Drug Administration, which receives taxpayer money from a separate spending bill and from industry user fees. In addition to giving HHS $8.5 billion in new funding, the bill also would add $2 billion to the National Institutes of Health's $39 billion budget.

The Centers for Disease Control and Prevention would see a $921 million increase, to $8.3 billion.

The bill includes report language on several key health provisions, including promoting the Orphan Drug Act and urging Centers for Medicare & Medicaid Services to support access to biologic and gene therapies for rare diseases with testing of health insurance benefit designs that eliminate specialty tiers.

The committee criticized a Trump administration proposed regulation that could affect Medicare Part D coverage of six therapeutic categories of drugs, including HIV, cancer, mental health conditions and other serious illnesses. The Trump proposal would allow increased use of prior authorizations and step therapy requirements that could delay access to these treatments, the committee said.

Added by Rep. Marcy Kaptur, D-Ohio, the committee report also would direct HHS to report on price changes of prescription drugs since 2008, including the 10 most frequently prescribed drugs and the 10 highest-cost drugs between ambulatory settings and retail settings.

ROMNEY BILL FOCUSES ON DRUG PRICE TRANSPARENCY

Sen. Mitt Romney, R-Utah, introduced legislation last week that he said would bring transparency to drug pricing and help reduce out-of-pocket costs for consumers at the pharmacy.

Some healthcare plans require enrollees to pay coinsurance, or a percentage of the total cost for prescription drugs. But the enrollee's coinsurance obligation is often based on a drug's list price, rather than the price net of rebates and discounts negotiated by pharmacy benefit managers and insurers.

The legislation, which was co-sponsored by Sen. Mike Braun, R-Ind., would require all patients' coinsurance obligations be set as a percentage of net price, rather than list price, before or after a deductible is met.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions